ReviewFrontiers in immunology2026
Predictive value of serum HBcrAg in antiviral therapy for chronic hepatitis B.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B (CHB) remains a significant global public health challenge. The goals of its antiviral therapy are gradually shifting from long-term viral suppression toward achieving safer treatment discontinuation, more accurate risk stratification, and deeper functional cure. Traditional serological markers, such as HBV DNA and HBsAg, remain clinically important in CHB. However, their ability to reflect residual viral activity and long-term outcomes is limited after long-term nucleos(t)ide analog (NA) therapy, especially in patients with sustained virological suppression or marked HBsAg decline or clearance.In recent years, hepatitis B core-related antigen (HBcrAg), due to its capacity to reflect transcriptional activity of intrahepatic covalently closed circular DNA(cccDNA) and the state of the residual viral reservoir, has emerged as a notable novel biomarker in the field of CHB. Concurrently, with the development of pegylated interferon (Peg-IFN) add-on strategies and novel combination cure approaches, the potential of HBcrAg in selecting optimal patient populations and monitoring therapeutic efficacy is increasingly recognized. This review focuses on the biological basis of HBcrAg and its main predictive values in CHB antiviral therapy. It also summarizes and prospects its clinical application potential and existing challenges based on current research progress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.